| Company Name: |
Hangzhou Peptidego Biotech Co.,Ltd.
|
| Tel: |
0571-87213919 |
| Email: |
Eric@peptidego.com |
| Products Intro: |
Product Name:AZD5582
CAS:1883545-51-4
Purity:95% or 98% HPLC Package:1mg；5mg；10mg；50mg；100mg,1g or according to customer's detail requirement.
|
AZD 5582 dihydrochloride manufacturers
|
| | AZD 5582 dihydrochloride Basic information |
| Product Name: | AZD 5582 dihydrochloride | | Synonyms: | AZD 5582 dihydrochloride;(2S,2'S)-N,N'-((1S,1'S,2R,2'R)-(Hexa-2,4-diyne-1,6-diylbis(oxy))bis(2,3-dihydro-1H-indene-2,1-diyl))bis(1-((S)-2-cyclohexyl-2-((S)-2-(methylamino)propanamido)acetyl)pyrrolidine-2-carboxamide) dihydrochloride;AZD5582 2HCl | | CAS: | 1883545-51-4 | | MF: | C58H79ClN8O8 | | MW: | 1051.77 | | EINECS: | | | Product Categories: | | | Mol File: | 1883545-51-4.mol |  |
| | AZD 5582 dihydrochloride Chemical Properties |
| storage temp. | Store at -20°C | | solubility | Soluble in DMSO | | form | Solid | | color | Off-white to light yellow |
| | AZD 5582 dihydrochloride Usage And Synthesis |
| Uses | AZD5582 dihydrochloride is an antagonist of the inhibitor of apoptosis proteins (IAPs), which binds to the BIR3 domains cIAP1, cIAP2, and XIAP with IC50s of 15, 21, and 15 nM, respectively. AZD5582 induces apoptosis[1]. | | in vivo | AZD5582 (intravenous injection; 0.1-3.0 mg/kg; once a week; 2 weeks) causes degradation of cIAP1 and caspase 3 cleavage in tumor cells, and after a two-week treatment, the tumors largely resolved; when the mice are given a medium dose (0.5 mg/kg) of AZD5582, cIAP1 degrades after administration, but it takes a while time to reach apoptosis-inducing effect[1]. | Animal Model: | MDA-MB-231 xenograft-bearing mice[1] | | Dosage: | 0.1 mg/kg, 0.5 mg/kg, 3.0 mg/kg | | Administration: | Intravenous injection; once a week; 2 weeks | | Result: | Resulted in cIAP1 degradation and caspase-3 cleavage within tumor cells and causes substantial tumor regressions following two weekly doses of 3.0 mg/kg |
| | IC 50 | cIAP1: 15 nM (IC50); cIAP2: 21 nM (IC50); XIAP: 15 nM (IC50) | | storage | Store at -20°C | | References | [1] Hennessy EJ, et al. Discovery of a novel class of dimeric Smac mimetics as potent IAP antagonists resulting in a clinical candidate for the treatment of cancer (AZD5582). J Med Chem. 2013 Dec 27;56(24):9897-919. DOI:10.1021/jm401075x
[2] Qin Hao, et al. IF-γ and Smac mimetics synergize to induce apoptosis of lung cancer cells in a TNFα-independent manner,Cancer Cell Int. 2018; 18: 84. DOI:10.1186/s12935-018-0579-y |
| | AZD 5582 dihydrochloride Preparation Products And Raw materials |
|